Topotecan for the treatment of relapsed small-cell lung cancer

National Institute for Health and Clinical Excellence

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
Oral topotecan is recommended as an option only for people with relapsed small-cell lung cancer for whom:
• re-treatment with the first-line regimen is not considered appropriate and
• the combination of cyclophosphamide, doxorubicin and vincristine (CAV) is contraindicated (for details of the contraindications to CAV see the summary of product characteristics for each of the component drugs).
Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.
People with relapsed small-cell lung cancer currently receiving oral topotecan who do not meet the criteria specified above, or who are receiving intravenous topotecan should have the option to continue their treatment until they and their clinicians consider it appropriate to stop.

Project page URL

Final publication URL
http://www.nice.org.uk/TA184

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Lung Neoplasms /drug therapy; Small Cell Lung Carcinoma /drug therapy; Topotecan /therapeutic use

Language Published
English

Country of organisation
England

Address for correspondence
National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800; Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk

AccessionNumber
32011000082

Date abstract record published
26/01/2011